RegeneRx Biopharmaceuticals, Inc (RGN)

[Trader0327]

RegeneRx's T4 Significantly Improves Functional Recovery in Multiple Sclerosis Animal Model
NEWS:

Press Release
Source: RegeneRx Biopharmaceuticals, Inc.
On Tuesday September 29, 2009, 11:42 am EDT
Buzz up! 0Print.Companies:Regenerx Biopharmaceuticals Inc.
BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today that researchers at the Henry Ford Health System in Detroit, Michigan, demonstrated for the first time that Tβ4 treatment of EAE (experimental autoimmune encephalomyelitis – an animal model for multiple sclerosis) significantly improves neurological functional recovery. In addition to this neurological benefit, the researchers reported a significant reduction of inflammation and induction of oligodendrogenesis (maturation of central nervous system cells associated with the formation of the nerve sheath), the control of which are important therapeutic goals.

http://finance.yahoo.com/news/RegeneRxs-T4-Significantly-bw-377571417.html?x=0&.v=1